

Foundation Medicine reports are tailored to regional needs and so may differ from the example shown.

Example report





- 1 **Biomarker findings.** TMB and MSI status, which may predict response to immunotherapy
- 2 **Genomic findings.** Clinically-relevant alterations in >300 tested cancer-related genes
- 3 **Pertinent negative results.** Rules out important alterations that are not present
- 4 **Therapies with clinical benefit.** Approved therapies for your patient's biomarkers and genomic alterations
- 5 **Clinical trials.** Relevant trials that your patient may be eligible for, based on their genomic profile and geographic location
- 6 **Genomic findings with no reportable options.** To help you rule out uncertainty and determine the most appropriate course of action



Gives important background information on **biomarkers and genomic alterations** in your patient's tumour, notably the evidence behind associated potential treatment strategies.

Provides evidence-based insights on the therapies that **match your patient's profile, in their tumour type and others.**



Details **ongoing clinical trials** that your patient may be eligible for, with trial NCT number, phase, title and locations.

Lists **variants of unknown significance (VUS)**, included in the event that they become clinically meaningful in the future.

Tells you **what we tested** to give you a comprehensive picture of our service.

FOR FURTHER DETAILS PLEASE CONTACT YOUR LOCAL AFFILIATE
 Visit rochefoundationmedicine.com

Foundation Medicine® and FoundationOne® are registered trademarks of Foundation Medicine®, Inc. Roche is the licensed distributor of Foundation Medicine® products outside of the United States